Private Insurance

Communicating the health needs of your child is the key element in educating your health insurance provider. Most often written documentation is the ideal way to educate your provider. Unfortunately, most health insurance providers are unfamiliar with the Dravet Spectrum Disorders and the unique medical needs. It is important to provide your health insurance provider with information to protect the continuity of quality care and access to medically necessary therapies for individuals with Dravet Spectrum Disorders. Equally important, is identifying a case manager or personnel familiar with rare and expensive conditions to assist you with the individual needs of your child or family member.

Supporting Research and Documents - Stiripentol

Scholarly research, medical journal articles, letters from the physician and documents can support your request for coverage of medically necessary (non-FDA approved), orphan designated drug therapies utilized in the treatment of Dravet Spectrum Disorders. These documents should be included in correspondence submitted to your private health insurance or Medicaid (including the EPSDT program).  

• Checklist for Parents
• Sample Request for Coverage of Medically Necessary Therapy Medicaid Approval Letters
• Private Insurer Approval Letters
• Sample Letter of Medical Necessity
• Approval Letters
• Stiripentol. Chiron C.
• Stiripentol in severe myoclonic epilepsy in infancy: a randomized placebo-controlled syndrome-dedicated trial.
• Long-term efficacy and tolerance of stiripentol in severe myoclonic epilepsy of infancy(Dravet syndrome)
• Stiripentol. A novel antiepileptic drug
• Cost Effectiveness of Stiripentol in Dravet
• Creating an Advocacy Campaign